AI Article Synopsis
- Heparin-induced thrombocytopenia (HIT) is diagnosed based on clinical signs like low platelet counts and thrombosis, along with tests for HIT antibodies.
- Recent approval of reimbursement for three new HIT antibody assay kits in Japan aims to improve diagnosis.
- The HemosIL kits utilize innovative techniques to detect various types of HIT antibodies and can help prevent the risk of reoccurrence in patients with a history of HIT.
Article Abstract
Heparin-induced thrombocytopenia (HIT) is a 'clinicopathologic syndrome'; therefore, its diagnosis depends on clinical criteria including the presence of thrombocytopenia and/or thrombosis and a pathological criterion implying the detectability of HIT antibodies. Recently, medical reimbursement (390 points) for assays of HIT antibodies using three new assay kits [HemosIL HIT-Ab(PF4-H), HemosIL AcuStar HIT IgG(PF4-H), HemosIL AcuStar HIT-Ab(PF4-H)] was approved in Japan. The HemosIL HIT-Ab(PF4-H) kit is a latex particle-enhanced immunoturbidimetric assay to detect total heparin-associated antibodies found in HIT patients. A monoclonal antibody that mimics human HIT antibodies is coated onto latex particles. HemosIL AcuStar HIT-IgG(PF4-H) (specific for IgG anti-PF4/heparin antibodies) and HemosIL AcuStar HIT Ab(PF4-H) (detecting IgG, IgM and IgA anti-PF4/heparin antibodies) are applicable to a fully automated quantitative chemiluminescent immnunoassay instrument 'ACL AcuStar'. HIT can be excluded in all patients by a negative antigen assay using HemosIL HIT-Ab(PF4-H) or HemosIL AcuStar HIT-Ab(PF4-H). Furthermore, in patients with previous HIT who require heparin treatment, pretesting by HemosIL HIT-Ab(PF4-H) or HemosIL AcuStar HIT-Ab(PF4-H) might be useful for preventing the onset of rapid-type HIT.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The dynamic range of immunoassays for heparin-induced thrombocytopenia.
J Thromb Haemost
November 2024
Department of Clinical Chemistry, Inselspital University Hospital Bern, Bern, Switzerland; Faculty of Medicine, University of Bern, Bern, Switzerland. Electronic address:
Article Synopsis
- The study evaluates the diagnostic significance of two immunoassay tests for heparin-induced thrombocytopenia (HIT) using data from 1393 patients, aiming to clarify the reliability of test results across their ranges.
- Findings reveal that while both assays correlate results to HIT diagnoses, the strength of this correlation differs, with the CLIA method showing a more pronounced increase in likelihood ratios compared to the ELISA method.
- A web-based calculator is provided to help clinicians estimate the probability of HIT based on individual test results, enhancing decision-making in patient care.
Is the combination of two automated rapid assays for diagnosis of heparin-induced thrombocytopenia necessary?
Blood Coagul Fibrinolysis
December 2024
Clinical Biochemistry Laboratory, Provincial Hospital of Bolzano (SABES-ASDAA), Bolzano, Italy.
Heparin-induced thrombocytopenia (HIT) is an immune-mediated condition characterized by a decrease in platelet count and an increased thrombotic risk. HIT event is caused by antiplatelet factor/heparin (PF4/H) antibodies that can activate the platelets. The diagnosis of HIT is based on a clinical evaluation and laboratory results.
View Article and Find Full Text PDFA comparative study of anti-ADAMTS-13 antibody dynamics in immune-mediated thrombotic thrombocytopenic purpura.
Res Pract Thromb Haemost
July 2024
Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Immunopathology and Cancer Biomarkers Unit, Department of Cancer Research and Advanced Diagnostics, Aviano, Italy.
Background: Thrombotic thrombocytopenic purpura, particularly its immune-mediated variant (iTTP), necessitates accurate diagnostic approaches for effective management.
Objectives: To compare a chemiluminescence immunoassay (CLIA) and an enzyme-linked immunosorbent assay (ELISA) for testing ADAMTS-13 activity and detecting anti-ADAMTS-13 autoantibodies (AAbs) in patients with iTTP.
Methods: This study involved 31 paired samples from 12 iTTP patients.
Practical Considerations for the Use of the Rapid AcuStar ADAMTS13 Activity Assay in the Diagnosis of Acute Thrombotic Thrombocytopenic Purpura (TTP).
J Clin Med
July 2024
The Roald Dahl Centre for Haemostasis and Thrombosis, Liverpool University Hospital NHS Trust, Liverpool L7 8XP, UK.
Article Synopsis
- Conventional management of acute TTP involves the immediate treatment of suspected cases while waiting for ADAMTS13 deficiency test results, with new rapid assays like the HemosIL AcuStar improving accessibility and diagnostic speed.
- A multi-centre study examined discrepancies between rapid (AcuStar) and traditional ELISA assays in patients suspected of TTP, highlighting that strong clinical suspicion correlates well with results while low suspicion may lead to inconsistencies.
- For patients with high suspicion of acute TTP, the AcuStar assay matched the ELISA results accurately, whereas discrepancies (particularly in cancer or sepsis cases) occurred when TTP suspicion was low, stressing the need for solid testing protocols in diagnosis.
Combination of 2 Quantitative Immunoassays and Clinical Score Algorithm to Reduce False-Negative Results in Heparin-Induced Thrombocytopenia: Prevalence Study of Mauriziano Hospital in Turin, Italy.
J Appl Lab Med
September 2024
SC Laboratorio Analisi, Azienda Ospedaliera Ordine Mauriziano, Turin, Italy.
Article Synopsis
- Heparin-induced thrombocytopenia (HIT) is a serious condition caused by antibodies that activate platelets and accurate diagnosis is crucial but difficult; this study aimed to assess a new diagnostic laboratory algorithm for suspected HIT using specific immunoassays.
- The study analyzed 163 patients, utilizing a two-step approach with Chemiluminescence (CliA) followed by ELISA testing to rule out or confirm HIT; the algorithm successfully excluded HIT in 88% of cases and made predictions about platelet aggregation in a subset of patients.
- The findings showed a HIT prevalence of 3.1%, consistent with existing literature, and indicated that the combined approach could quickly rule out HIT in a majority of patients, although individual
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!